A dual-modal graph learning framework for identifying interaction events among chemical and biotech drugs

Drug-drug interaction (DDI) identification is essential to clinical medicine and drug discovery. The two categories of drugs (i.e. chemical drugs and biotech drugs) differ remarkably in molecular properties, action mechanisms, etc. Biotech drugs are up-to-comers but highly promising in modern medicine due to higher specificity and fewer side effects. However, existing DDI prediction methods only consider chemical drugs of small molecules, not biotech drugs of large molecules. Here, we build a large-scale dual-modal graph database named CB-DB and customize a graph-based framework named CB-TIP to reason event-aware DDIs for both chemical and biotech drugs. CB-DB comprehensively integrates various interaction events and two heterogeneous kinds of molecular structures. It imports endogenous proteins founded on the fact that most drugs take effects by interacting with endogenous proteins. In the modality of molecular structure, drugs and endogenous proteins are two heterogeneous kinds of graphs, while in the modality of interaction, they are nodes connected by events (i.e. edges of different relationships). CB-TIP employs graph representation learning methods to generate drug representations from either modality and then contrastively mixes them to predict how likely an event occurs when a drug meets another in an end-to-end manner. Experiments demonstrate CB-TIP's great superiority in DDI prediction and the promising potential of uncovering novel DDIs.

[1]  Tudor I. Oprea,et al.  Novel drug targets in 2022 , 2023, Nature reviews. Drug discovery.

[2]  Xiangxiang Zeng,et al.  DSN-DDI: an accurate and generalized framework for drug-drug interaction prediction by dual-view representation learning , 2023, Briefings Bioinform..

[3]  Xin Dong,et al.  Small molecule drug and biotech drug interaction prediction based on multi-modal representation learning , 2022, BMC Bioinformatics.

[4]  Kuan-Fu Chen,et al.  Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator , 2022, CPT: pharmacometrics & systems pharmacology.

[5]  Tudor I. Oprea,et al.  Novel drug targets in 2021 , 2022, Nature Reviews Drug Discovery.

[6]  Hui Yu,et al.  RANEDDI: Relation-aware network embedding for drug-drug interaction prediction , 2022, Inf. Sci..

[7]  Jian-Yu Shi,et al.  Drug-drug interaction prediction with learnable size-adaptive molecular substructures , 2021, Briefings Bioinform..

[8]  Tudor I. Oprea,et al.  Novel drug targets in 2020 , 2021, Nature Reviews Drug Discovery.

[9]  F. Albericio,et al.  The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules , 2021, Molecules.

[10]  Xin Chen,et al.  Multi-view Graph Contrastive Representation Learning for Drug-Drug Interaction Prediction , 2020, WWW.

[11]  Jimeng Sun,et al.  SumGNN: multi-typed drug interaction prediction via efficient knowledge graph summarization , 2020, Bioinform..

[12]  Xiaomin Luo,et al.  Pushing the boundaries of molecular representation for drug discovery with graph attention mechanism. , 2020, Journal of medicinal chemistry.

[13]  Eytan Ruppin,et al.  Discovery of SARS-CoV-2 Antivirals through Large-scale Drug Repositioning , 2020, Nature.

[14]  Xiangxiang Zeng,et al.  KGNN: Knowledge Graph Neural Network for Drug-Drug Interaction Prediction , 2020, IJCAI.

[15]  Xiaofeng Wang,et al.  Drug–target affinity prediction using graph neural network and contact maps , 2020, RSC advances.

[16]  Tudor I. Oprea,et al.  Novel drug targets in 2019 , 2020, Nature Reviews Drug Discovery.

[17]  Yizhou Sun,et al.  Heterogeneous Graph Transformer , 2020, WWW.

[18]  F. Albericio,et al.  The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules , 2020, Molecules.

[19]  Jimeng Sun,et al.  CASTER: Predicting Drug Interactions with Chemical Substructure Representation , 2019, AAAI.

[20]  Tudor I. Oprea,et al.  Novel drug targets in 2018 , 2019, Nature reviews. Drug discovery.

[21]  Mihai Udrescu,et al.  A Drug Repurposing Method Based on Drug-Drug Interaction Networks and Using Energy Model Layouts. , 2018, Methods in molecular biology.

[22]  Jure Leskovec,et al.  How Powerful are Graph Neural Networks? , 2018, ICLR.

[23]  Weilin Huang,et al.  Deep Metric Learning with Hierarchical Triplet Loss , 2018, ECCV.

[24]  Thorsten Lehr,et al.  PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin , 2018, CPT: pharmacometrics & systems pharmacology.

[25]  S. Garneau‐Tsodikova,et al.  What are the drugs of the future? , 2018, MedChemComm.

[26]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[27]  Jae Yong Ryu,et al.  Deep learning improves prediction of drug–drug and drug–food interactions , 2018, Proceedings of the National Academy of Sciences.

[28]  Jure Leskovec,et al.  Modeling polypharmacy side effects with graph convolutional networks , 2018, bioRxiv.

[29]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[30]  Gaelen T. Hess,et al.  Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions , 2017, Nature Biotechnology.

[31]  Max Welling,et al.  Modeling Relational Data with Graph Convolutional Networks , 2017, ESWC.

[32]  Hui Liu,et al.  Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks , 2016, BMC Bioinformatics.

[33]  Tudor I. Oprea,et al.  A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.

[34]  Naomi S. Altman,et al.  Points of Significance: Classification evaluation , 2016, Nature Methods.

[35]  Sebastian Nowozin,et al.  f-GAN: Training Generative Neural Samplers using Variational Divergence Minimization , 2016, NIPS.

[36]  M. Steinman Polypharmacy-Time to Get Beyond Numbers. , 2016, JAMA internal medicine.

[37]  Jocelyn R. Wilder,et al.  Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011. , 2016, JAMA internal medicine.

[38]  Jian Sun,et al.  Deep Residual Learning for Image Recognition , 2015, 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR).

[39]  George Hripcsak,et al.  Similarity-based modeling in large-scale prediction of drug-drug interactions , 2014, Nature Protocols.

[40]  Markus Gruber,et al.  CCMpred—fast and precise prediction of protein residue–residue contacts from correlated mutations , 2014, Bioinform..

[41]  Hongkang Mei,et al.  Systematic Prediction of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction Network , 2013, PLoS Comput. Biol..

[42]  R. Sharan,et al.  INDI: a computational framework for inferring drug interactions and their associated recommendations , 2012, Molecular systems biology.

[43]  M. Rask-Andersen,et al.  Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.

[44]  L. Deckelbaum,et al.  Effect of nesiritide in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[45]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[46]  Jiunn H Lin,et al.  Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. , 2009, Current drug metabolism.

[47]  Allen Huang,et al.  The challenge of managing drug interactions in elderly people , 2007, The Lancet.

[48]  Benno Schwikowski,et al.  Graph-based methods for analysing networks in cell biology , 2006, Briefings Bioinform..

[49]  L. Rubin Epoprostenol and nesiritide in pulmonary hypertension. , 2005, Chest.

[50]  E. Ernst,et al.  Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. , 2005, International journal of cardiology.

[51]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[52]  G. Jang,et al.  Pharmacokinetics and its role in small molecule drug discovery research , 2001, Medicinal research reviews.

[53]  L. Korcek,et al.  Thyroxine-protein interactions. Interaction of thyroxine and triiodothyronine with human thyroxine-binding globulin. , 1976, The Journal of biological chemistry.

[54]  OUP accepted manuscript , 2022, Briefings In Bioinformatics.

[55]  Y. Nabuchi,et al.  Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. , 2009, Drug metabolism and pharmacokinetics.